Drug Search Results
More Filters [+]

Abediterol

Alternative Names: abediterol, las100977
Latest Update: 2020-04-21
Latest Update Note: Clinical Trial Update

Product Description

Abediterol is a novel, once-daily long-acting ?2-agonist in development for the treatment of chronic obstructive pulmonary disease (COPD) and asthma in combination with an anti-inflammatory agent.

Mechanisms of Action: ADRB2 Agonist

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Inhalant

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: AstraZeneca
Company Location: CAMBRIDGE X0 CB2 0AA
Company CEO: Pascal Soriot
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Abediterol

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Asthma|Chronic Obstructive Pulmonary Disease

Phase 1: Chronic Obstructive Pulmonary Disease|Asthma

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

2006-7041-83/hah

N/A

Not yet recruiting

Cholangitis, Sclerosing|Oral Ulcer|Colitis, Ulcerative

2022-12-30

D6541C00001

P1

Terminated

Chronic Obstructive Pulmonary Disease

2020-04-03

52%

D6540C00006

P1

Completed

Asthma

2017-11-09

D7110C00001

P1

Completed

Chronic Obstructive Pulmonary Disease|Asthma

2017-04-06

52%

Recent News Events

Date

Type

Title